---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-290768"
form_type: "8-K"
ticker: "CPRX"
cik: "0001369568"
company_name: "CATALYST PHARMACEUTICALS, INC."
filed_at: "2026-06-30T20:57:55+00:00"
generated_at: "2026-06-30T20:59:03.821352+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Catalyst Pharma: Vamorolone Phase 1 shows glucocorticoid activity without immunosuppression at clinical doses

## Summary
- Phase 1 study: vamorolone 300 mg vs deflazacort 0.9 mg/kg showed comparable cortisol suppression.
- No significant immunosuppressive effects at clinical doses (9 or 27 mg/kg/day); only at 40 mg/kg/day.
- Data support current vamorolone dosing in DMD and potential for broader chronic inflammatory indications.
- Study enrolled 24 healthy adults (Part A) and 36 volunteers (Part B) with ascending doses.

## SEC filing metadata
- accession: 0001193125-26-290768
- form_type: 8-K
- ticker: CPRX
- cik: 0001369568
- company_name: CATALYST PHARMACEUTICALS, INC.
- filed_at: 2026-06-30T20:57:55+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369568/000119312526290768/0001193125-26-290768-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369568/000119312526290768/d158010d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-290768
- JSON: https://secwatch.observer/filing/0001193125-26-290768.json
- Plain text: https://secwatch.observer/filing/0001193125-26-290768.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.